RNAZTransCode Therapeutics, Inc.
2.870USD-10.59%Mkt Cap: 3.04M $P/E: —3d ago
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for …